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Conclusions: Predictors for subsequent 5-year disabling course are 
an age below 40 years, the initial requirement for corticosteroids, 
and jejunal involvement in Korean patients with CD. Further pro-
spective validation of these parameters is warranted.
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Background: Ileocaecal Crohn's disease (CD) with disease activ-
ity confined to the terminal ileum, with or without caecal involve-
ment, can be treated either surgically or medically. However, little is 
known about the timing of surgery or benefits of surgery compared 
to medical treatment. The aims of this study were to assess outcomes 
after medical versus surgical management of ileocaecal CD in the 
current era.
Methods: Of 885 patients with CD diagnosed and prospectively 
enrolled in our hospital between 1980 and 2013, 93 (10.5%) ile-
ocaecal CD patients were identified. Those who had a follow-up 
shorter than 6 months were excluded (n = 5). Patients were assigned 
to either medical or surgical remission group by initial management 
strategy that had leaded to remission. Relapse, hospitalization, and 
surgery rates after medically or surgically induced remission were 
compared using Kaplan-Meier curve with log-rank test.
Results: Patients assigned to surgical and medical remission groups 
were 15 (17.0%) and 73 (83.0%), respectively. Median follow up 
duration was 6.6 years (interquartile range, 3.1 - 9.9 years). In total, 
relapse occurred in 48 (54.5%) patients, and the median time to 
relapse was 3.9  years (95% confidence interval, 3.1 - 4.7  years). 
Surgical remission group showed a lower relapse rate with pro-
longed maintenance of remission (10.7 vs. 3.7  years; P  =  0.017). 
Hospitalization after first remission tended to be lower in surgical 
remission group (P = 0.054), and there was no case with repeated 
intestinal resection after initial surgical remission strategy, whereas 
23% and 39% of surgery rates were reported at 5 and 10 years after 
initial medical treatment (P = 0.037). At multivariate analysis, initial 
medical management strategy (Hazard ratio [HR] = 3.23, P = 0.039) 
were strongly associated with relapse in ileocaecal CD, along with a 
younger age at diagnosis (HR = 1.06, P = 0.003) and a longer time 
to achieve first remission (HR = 1.04, P = 0.013).
Conclusions: Overall outcomes of ileocaecal CD are excellent with 
44.5% of patients remaining symptom-free at 5  years after first 
remission. In selected cases of localised ileocaecal CD, ileocolic resec-
tion might be a good alternative to the long-term medical treatment, 
with a lower relapse rate and prolonged maintenance of remission.
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Background: The interest in calprotectin is constantly increasing 
due to its potential as a non-invasive, cheap and sensitive marker 
for intestinal inflammation. Currently, calprotectin is measured with 
commercially available ELISA and EliA assays. At present, these 
Methods are time-consuming and used only in clinical laboratories. 
Determination of calprotectin in stool requires often manual and 
long pre-analytical processing of the fecal samples, which may lead 
to long turn-a-round time for the calprotectin Results. We have vali-
dated a new chemiluminescent immunoassay for determination of 
calprotectin in combination with fully automatic system for pre-
analytical processing of fecal samples in order to improve efficiency 
and generate shorter turn-a-round time for the calprotectin Results.
Methods: A  new chemiluminescent immunoassay assay (DiaSorin 
S.p.a.) for determination of calprotectin was validated on LIAISON 
XL Analyzer (DiaSorin S.p.a.). Pre-analytical processing of fecal 
samples was performed with a fully automated robotic system 
(SoniC, S2G Scandinavia), which perform weighing, homogeniza-
tion and centrifugation of stool samples.
Results: Assay linearity was proven throughout the measuring range 
from 5 to 800 mg/kg. Samples with higher levels of calprotectin are 
automatically diluted and reanalyzed. Within-run CVs ranged from 
3,8-4,7 %, for concentrations of 40- and 160 mg/kg and total CV 
was calculated to 5 %.
The LIAISON Calprotectin assay shows good precision between 
duplicates. 90 samples with the concentrations between 5 mg/kg and 
5000 mg/kg were analyzed and CV was calculated to 2%. The assay 
was compared to the ELISA assay that is currently used in the labo-
ratory (BÜHLMANN Laboratories AG). Results obtained with the 
chemiluminescent immunoassay showed lower values then Results 
obtained with ELISA (slope=1,8, R2 = 0,79, n=85 (conc. range 5- 
5000 mg/kg), slope = 2,8, R2 = 0,81, n=66 (conc. range 5-300 mg/
kg)).
Our laboratory yearly analyze 15 000 calprotectin samples. The 
turn-around-time for calprotectin Results could be significantly 
decreased, from 2-3 weeks to 2-3 days when using automatic sys-
tem for processing of stool samples and new LIAISON Calprotectin 
assay for measurement of calprotectin in stool.
Conclusions: The chemiluminescent immunoassay for measurement 
of Calprotectin in stool was shown to be precise with proven linear-
ity over the measuring range. The automation of both pre-analytical 
processing of stool samples and measurement of calprotectin con-
centration resulted in improved efficiency and significantly shorter 
turn-around-time for calprotectin Results.
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Background: Studies evaluating risk factors associated with an 
"aggressive" disease course in ulcerative colitis (UC) are scarce. 
A recent definition of "aggressive" UC incorporated the following 
characteristics: 1) high relapse rate, 2) need for surgery, 3) develop-
ment of colorectal cancer, and 4) presence of extraintestinal mani-
festations (EIM). The following factors for an aggressive / disabling 
disease course in UC have been identified so far: age < 40 years at 
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UC diagnosis, pancolitis, concomitant primary sclerosing cholangi-
tis, and deep ulcerations of the colonic mucosa. We aimed to evalu-
ate risk factors for an "aggressive" disease course in UC patients.
Methods: Data from the Swiss IBD cohort study were analyzed. 
Patients were recruited from university centers (80%), regional hos-
pitals (19%), and private practices (1%). We applied the following 
definition for "aggressive" UC: 1) patients ever treated with TNF-
antagonists or calcineurin inhibitors (tacrolimus / cyclosporine), and 
2) need for (procto)-colectomy. Non-normal data are presented as 
median and interquartile range [IQR].
Results: A total of 1,130 adult UC patients were included. Of these, 
422 (37.3%) had an aggressive disease course. UC patients with 
aggressive disease course were characterized by the following features 
when compared to UC patients with non-aggressive disease course: 
more frequently males (59.2% vs. 50.6%, p = 0.005), younger at UC 
diagnosis (median 28 years vs. 33 years, p < 0.001), more frequently 
< 40  years at diagnosis (79.8% vs. 72.1%, p  =  0.004), more fre-
quently pancolitis at diagnosis (51% vs. 37.1%, p <0.001), younger 
age at latest follow-up (median 41 years vs. 46 years, p < 0.001), 
and had more frequently extraintestinal manifestations (52.6% vs. 
36.3%, p < 0.001). No difference was found between the two groups 
when analyzing the length of diagnostic delay, body mass index, 
NSAID intake at symptom onset, disease duration (both median of 
10  years), geographical provenience (urban vs. rural), and educa-
tion level. UC patients with aggressive disease course were more 
frequently treated with antibiotics (40.3% vs. 18.6%, p < 0.001), 
with steroids (92.4% vs. 72.2%, p < 0.001), and immunomodulators 
(80.6% vs. 47.5%, p <0.001).
Conclusions: Our large cohort study confirmed the following risk 
factors for "aggressive" disease course: young age at diagnosis, 
extensive colitis / pancolitis at diagnosis, and presence of extraintes-
tinal manifestations. In addition, our study identified male gender 
to be a risk factor for "aggressive" disease course. Further studies 
will have to show if early stepup therapy is beneficial in UC patients 
fulfilling criteria for "aggressive" disease course.
P130
Persistent Enhancement in Contrast Ultrasound 
Studies of Severe Crohn's Disease: Stuck 
Bubbles?
R. Wilkens*1, 2, 3, 4, A. Wilson1, P.N. Burns5, S. Ghosh2, S.R. Wilson1, 2
1University of Calgary, Department of Radiology, Calgary, Canada, 
2University of Calgary, Department of Medicine, Division of 
Gastroenterology, Calgary, Canada, 3Regional Hospital Silkeborg, 
University Research Clinic for Innovative Patient Pathways, 
Diagnostic Center, Division of Gastroenterology, Silkeborg, 
Denmark, 4Aarhus University Hospital, Department of Hepatology 
and Gastroenterology, Aarhus, Denmark, 5University of Toronto, 
Department of Biophysics and Imaging Research, Toronto, Canada
Background: Our aim is to describe a unique observation on con-
trast-enhanced ultrasound (CEUS), seen in a small population of 
patients with severe Crohn Disease (CD) in whom contrast enhance-
ment does not show typical decline over time. Clinical significance 
is assessed. We hypothesize the non-targeted microbubbles adhere to 
the site of inflammation, [1] as previously shown in animal models 
with induced inflammation. [2] [3]
Methods: From an existing CD study cohort examined with CEUS 
for determination of disease extent and activity, 17 patients show 
high peak enhancement (PE), over 23 dB, consistent with severe 
active disease, but with minimal decline over a 3 minute interval. 
From the same cohort, a matching control group of 19 patients with 
the same PE but typical washout were selected. Original cineloop 
“Box plot differences in time intensity curve details between study patients (cases) and control patients.”
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